(4,6-dimethoxypyidin-3-yl)methanol 在
manganese dioxide silica gel 、 ethyl acetate n-hexane 作用下,
以
甲苯 为溶剂,
反应 16.0h,
以to give 300 mg of the title compound (and starting material recovery 1.59 g)的产率得到4,6-dimethoxy-pyridine-3-carbaldehyde
The present invention provides a compound represented by the formula (1) or a pharmacologically acceptable salt thereof, or a hydrate thereof (provided that a compound in which all of R4a, R4b, and R4c are hydrogen atoms is excluded.):
[wherein R1 represents a hydrogen atom, R2 represents a hydrogen atom, R3 represents the formula:
wherein R4a, R4b, and R4c are the same as or different from each other and each represents a hydrogen atom, a C
1-6
alkyl group or a C
1-6
alkoxy group, etc.]
The invention relates to aryl substituted heterocyclyl sulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
The present invention provides a compound represented by the formula (1) or a pharmacologically acceptable salt thereof, or a hydrate thereof (provided that a compound in which all of R4a, R4b, and R4c are hydrogen atoms is excluded.):
[wherein R1 represents a hydrogen atom, R2 represents a hydrogen atom, R3 represents the formula:
wherein R4a, R4b, and R4c are the same as or different from each other and each represents a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group, etc.]